Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0047-0740(75)90032-7 | DOI Listing |
J Oncol Pharm Pract
December 2024
Hospital Pharmacy Department, Fundación Onkologikoa, Donostia, Gipuzkoa, Spain.
Introduction: Intravenous (IV) medications can be prepared using compounding devices to increase productivity, and reduce risks associated with aseptic compounding. This study evaluated the productivity and quality outcomes of the aseptic process for simulated batches of IV medications used in clinical practice produced using a semi-automated compounding device (Gri-fill; Grifols).
Methods: Simulated batches from 50 to 600 preparations were completed representing hazardous and non-hazardous drugs, including one-step single component (atropine sulfate, cisplatin) and multistep, multiple component (mitomycin C, piperacillin/tazobactam, trastuzumab, 5-fluorouracil and gemcitabine).
ACS Nano
September 2024
Department of Biomedical Engineering, College of Engineering, University of Arkansas, Fayetteville, Arkansas 72701, United States.
This study evaluates the use of poly(vinyl alcohol), collagen, and chitosan blends for developing a microneedle patch for the delivery of meloxicam (MEL). Results confirm successful MEL encapsulation, structural integrity, and chemical stability even after ethylene oxide sterilization. Mechanical testing indicates the patch has the required properties for effective skin penetration and drug delivery, as demonstrated by load-displacement curves showing successful penetration of pig ear surfaces at 3N of normal load.
View Article and Find Full Text PDFFront Cell Infect Microbiol
August 2024
Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, České Budějovice, Czechia.
Medicine (Baltimore)
August 2024
Department of Urology and Andrology, Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, P. R. China.
Contemp Clin Trials
June 2024
Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, School of Medicine, United States of America; Moores Cancer Center, University of California San Diego, United States of America.
Introduction: Children, adolescent, and young adult cancer survivors experience overall increased risks of infertility that are preventable through effective fertility preservation services prior to starting cancer treatment. Oncofertility care is the evidence-based practice of informing newly diagnosed cancer patients about their reproductive risks and supporting shared decision-making on fertility preservation services. Despite longstanding clinical guidelines, oncofertility care delivery continues to be limited and highly variable across adult and pediatric oncology settings.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!